ImmuCell
ImmuCell's revenue rose 4.3% to $28 million in fiscal 2025. Its operating margin was 6.0%, up from −6.2% a year earlier. Free cash flow was $1 million. The diluted share count rose 10.5%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
ImmuCell lost money in fiscal 2025: a net loss of $1 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 10 | 6 | 1 | 4 | 4 |
| Debt incl. finance leases | 1 | 19 | 22 | — | 9 |
| Net debt (negative means net cash) | −9 | 13 | 21 | — | 5 |
| Net debt to EBITDA | −3.5x | 70.7x | — | — | 1.2x |
| Debt to equity | 0.0x | 0.6x | 0.9x | — | 0.3x |
| Interest coverage | 0.8x | −6.6x | −12.1x | −2.9x | 3.3x |
| Current ratio | 6.4x | 4.6x | 2.7x | 3.4x | 4.3x |
| Quick ratio | 5.2x | 2.6x | 0.9x | 1.8x | 1.9x |
Cash flow
Projections
Project ImmuCell's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 2 insiders bought $140,146 of ImmuCell shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jun 18, 2026 | Boekhorst Paul Francis Olivier tePresident and CEO, Director | Bought | 8,000 | $9.50 | $76,000 | Form 4 |
| Dec 3, 2025 | Boekhorst Paul Francis Olivier tePresident and CEO, Director | Bought | 6,077 | $5.02 | $30,526 | Form 4 |
| Dec 2, 2025 | Boekhorst Paul Francis Olivier tePresident and CEO, Director | Bought | 3,708 | $4.87 | $18,058 | Form 4 |
| Nov 25, 2025 | David Scott TomscheDirector | Bought | 3,266 | $4.76 | $15,562 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 1 of 9 | — | — |
| Rule of 40 | −43.5% | 51.2% | 8.8% |
| Altman Z'' | 0.71 | 1.92 | 2.93 |
| Accruals ratio | −2.5% | −5.7% | −8.0% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Pass | Pass |
| Return on assets rose | Fail | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | — | — |
| Current ratio rose | Fail | Pass | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Pass | Pass |
| Revenue rose relative to assets | Fail | Pass | Pass |
| F-score | 1 of 9 | — | — |
Compare
Put ImmuCell side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| ImmuCell | FY25 | 4.3% | 6.0% | 4.4% | — | 1.2x | — | |
| Alpha Pro Tech | FY25 | 2.2% | 6.5% | 2.9% | — | — | — | Compare |
| RxSight | FY25 | −3.9% | −35.8% | −14.4% | −82.9% | — | 3 | Compare |
| Insight Molecular Diagnostics | FY25 | 115.6% | −1,260.8% | −625.6% | — | — | — | Compare |
| VolitionRx | FY25 | 40.0% | −1,258.5% | −1,144.7% | — | — | 2 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 10 | 10 | 11 | 14 | 15 | 19 | 19 | 18 | 26 | 28 |
| Revenue growth | −6.7% | 9.3% | 5.3% | 24.9% | 11.8% | 25.4% | −3.5% | −5.9% | 51.6% | 4.3% |
| Gross profit | 5 | 5 | 5 | 7 | 7 | 9 | 8 | 4 | 8 | 11 |
| Research and development | 1 | 2 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 |
| Operating income | 1 | −0 | −1 | −1 | −1 | 0 | −2 | −6 | −2 | 2 |
| Net income | 0 | −0 | −2 | −1 | −1 | −0 | −2 | −6 | −2 | −1 |
| Diluted EPS (US$) | 0.12 | −0.03 | −0.42 | −0.19 | −0.14 | −0.01 | −0.32 | −0.75 | −0.26 | −0.12 |
| Diluted shares (millions) | 4 | 5 | 6 | 7 | 7 | 8 | 8 | 8 | 8 | 9 |
| Cash flow | ||||||||||
| Cash from operations | −0 | 1 | −0 | 0 | 1 | 1 | −2 | −5 | 0 | 2 |
| Capital expenditure | 4 | 18 | 2 | 1 | 4 | 3 | 4 | 2 | 0 | 1 |
| Free cash flow | −4 | −17 | −2 | −1 | −3 | −2 | −6 | −7 | −0 | 1 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 11 | 4 | 2 | 9 | 8 | 10 | 6 | 1 | 4 | 4 |
| Debt incl. finance leases | — | 9 | 9 | 8 | 10 | 1 | 19 | 22 | — | 9 |
| Total assets | 25 | 34 | 33 | 39 | 40 | 44 | 45 | 44 | 45 | 42 |
| Total liabilities | 5 | 11 | 11 | 10 | 12 | 12 | 14 | 19 | 18 | 16 |
| Shareholders' equity | 20 | 24 | 22 | 29 | 28 | 33 | 30 | 25 | 28 | 27 |
| Margins and ratios | ||||||||||
| Gross margin | 56.8% | 50.1% | 47.3% | 49.1% | 44.7% | 45.0% | 41.2% | 22.1% | 30.0% | 41.4% |
| Operating margin | 9.3% | −2.3% | −13.2% | −7.0% | −9.0% | 1.3% | −12.4% | −32.9% | −6.2% | 6.0% |
| Net margin | 5.3% | −1.6% | −21.1% | −9.4% | −6.7% | −0.4% | −13.4% | −33.0% | −8.1% | −3.8% |
| Free cash flow margin | −39.9% | −159.0% | −21.9% | −8.4% | −18.0% | −8.6% | −29.7% | −37.6% | −0.4% | 4.4% |
| Rule of 40 (growth + FCF margin) | −46.6% | −149.7% | −16.6% | 16.5% | −6.2% | 16.8% | −33.2% | −43.5% | 51.2% | 8.8% |
| Return on capital | — | — | −4.0% | −2.6% | −3.7% | 0.8% | −5.4% | −10.1% | — | — |
| Return on equity | 3.4% | −0.8% | −10.2% | −5.1% | −3.6% | −0.3% | −7.9% | −20.9% | −8.2% | −3.8% |
| Return on assets | 2.6% | −0.6% | −6.9% | −3.6% | −2.6% | −0.2% | −5.6% | −13.0% | −4.8% | −2.4% |
| Net debt to EBITDA | — | 7.8x | 91.0x | −0.3x | 1.6x | −3.5x | 70.7x | — | — | 1.2x |